Lyme disease cases in England have surged by over 20% in a year, according to recent data from the UK Health Security Agency (UKHSA). This alarming trend has sparked renewed interest in the development of new vaccines and drugs to combat the tick-borne illness. The rise in cases, from 959 in 2024 to 1,168 in 2025, mirrors the previous year's figure, indicating a persistent challenge in managing this disease.
Dr Claire Gordon, head of the rare and imported pathogens laboratory at UKHSA, attributes the increase to various factors. She notes that the geographical distribution of ticks is expanding, influenced by weather conditions, climate trends, habitat changes, and host population shifts. The symptoms of Lyme disease, including a distinctive bullseye-like rash, fever, muscle and joint pain, and lethargy, can be challenging to diagnose, and left untreated, may lead to chronic issues.
The article delves into the complexities of Lyme disease management, highlighting the differences between veterinary and human approaches. Linden Hu, a professor of immunology, explains that pet owners are more inclined to medicate their pets, while human clinical trials are more challenging due to the difficulty in controlling the environment and the unpredictability of Lyme cases. This leads to the discussion of the LYMErix vaccine, which was previously available in the US but withdrawn due to low uptake and concerns about potential side effects.
The piece also explores the development of new treatments, including an mRNA vaccine from Moderna and a vaccine from Pfizer and Valneva. These efforts aim to address the potential side effects of LYMErix and improve vaccine efficacy. Additionally, the article introduces a drug called lotilaner, developed by Tarsus Pharmaceuticals, which kills ticks before they can transmit the disease, offering a novel approach to Lyme disease prevention.
However, the article raises questions about the future of Lyme disease management in the UK. Julia Knight from Lyme Disease UK suggests that the low reported figures may be an underestimation, as many cases go undiagnosed. The article concludes by emphasizing the ongoing need for scientific advancements in Lyme disease prevention and the challenges of navigating public trust and vaccine hesitancy in the current climate.
